Head-to-head evidence
guselkumab vs mirikizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
QUASAR/GALAXI · Phase 3 · completed
Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT06260163 (registry estimate)
mirikizumab · Omvoh
Marketed by Eli Lilly
NCT03524092 · Phase 3 · completed
Randomized (re-randomization of induction responders), double-blind, placebo-controlled, adequately powered (n=544 in the key comparison), hard composite clinical/endoscopic primary endpoint that was statistically significant in the favorable direction (p<0.001) — meeting the 'strong' definition's full test.
Next expected readout: May 2027 · NCT07186101 (registry estimate)
Crohn's Disease
Shared mechanism: IL-23 p19 · full Crohn's Disease pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
QUASAR/GALAXI · Phase 3 · completed
Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: March 2027 · NCT05347095 (registry estimate)
mirikizumab · Omvoh
Marketed by Eli Lilly
NCT03926130 · Phase 3 · completed
Randomized, triple-masked, placebo-controlled, adequately powered (n=1158 overall, ~778 in the placebo/mirikizumab primary comparison), with hard endoscopic (SES-CD response) and clinical remission co-primary endpoints, both meeting statistical significance (p<0.000001) favoring mirikizumab over placebo.
Next expected readout: June 2027 · NCT07483099 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: guselkumab's landscape · mirikizumab's landscape